Karuna Labs

Executive Summary

Karuna Labs addresses the widespread chronic pain epidemic through a novel digital therapeutic approach grounded in neuroplasticity. Their 12-week program combines evidence-based pain reprocessing techniques, state-of-the-art technology (including VR and mobile apps), and personalized coaching to help patients retrain their brains and reduce pain perception. This non-pharmacological, non-invasive solution tackles opioid dependency and offers a scalable alternative to traditional pain management. With a compassionate, data-driven model, Karuna is positioned to capture a significant share of the $60B+ chronic pain market. The company’s early traction and growing clinical evidence base suggest strong product-market fit, though competition from other digital health platforms remains a risk.

Upcoming Catalysts (preview)

• Q2 2026Completion of a pivotal clinical trial demonstrating clinically meaningful pain reduction70% success
• Q3 2026Strategic partnership with a national health insurer to include Karuna in coverage networks50% success
• Q4 2026Launch of an AI-enhanced personalized coaching feature to improve patient engagement and outcomes60% success